- Trials with a EudraCT protocol (108)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
108 result(s) found for: Musculoskeletal Abnormalities.
Displaying page 1 of 6.
EudraCT Number: 2013-001064-27 | Sponsor Protocol Number: s55283 | Start Date*: 2013-06-25 |
Sponsor Name:University Hospitals Leuven | ||
Full Title: Placebo-controlled trial with vitamin D to prevent worsening/relieve aromatase inhibitor-induced musculoskeletal symptoms in breast cancer patients | ||
Medical condition: aromatase inhibitor-induced musculoskeletal symptoms in postmenopausal breast cancer patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: BE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2010-019109-40 | Sponsor Protocol Number: XC0409 | Start Date*: 2011-03-25 | |||||||||||
Sponsor Name:Xenome Ltd | |||||||||||||
Full Title: A multicenter, randomized, observer-blinded, single-dose, placebo-controlled, sequential cohort study of the efficacy and safety of Xen2174 in subjects following bunionectomy surgery | |||||||||||||
Medical condition: Moderate to severe acute post-operative pain in subjects following primary unilateral first metatarsal bunionectomy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001764-11 | Sponsor Protocol Number: PTC124-GD-030-DMD | Start Date*: 2020-01-21 | ||||||||||||||||
Sponsor Name:PTC Therapeutics, Inc. | ||||||||||||||||||
Full Title: A Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ataluren (PTC124®) in Patients Aged ≥2 to <5 Years Old With Nonsense Mutation Dystrophinopathy | ||||||||||||||||||
Medical condition: nonsense mutation dystrophinopathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000737-40 | Sponsor Protocol Number: BAY12-8039/11826 | Start Date*: 2012-02-20 |
Sponsor Name:Bayer HealthCare Pharmaceuticals | ||
Full Title: Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients | ||
Medical condition: No medical condition specified as the purpose of this study is to describe the pharmacokinetics of moxifloxacin in children for future antibiotic treatment. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2015-004359-32 | Sponsor Protocol Number: 230LE201 | Start Date*: 2017-02-01 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in... | |||||||||||||
Medical condition: Systemic Lupus Erythematosus (SLE) with Active Skin Manifestations and Active Cutaneous Lupus Erythematosus (CLE) with or without Systemic Manifestations | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004017-17 | Sponsor Protocol Number: RR11/9965 | Start Date*: 2013-04-08 |
Sponsor Name:The University of Leeds | ||
Full Title: Prospective, Single-centre, Open-Label, Randomised, Pilot Study Assessing the changes in expression of JAK-STAT and Speed & Depth of Remission Induced by Tocilizumab & Methotrexate Combination and ... | ||
Medical condition: Rheumatoid Arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-004885-14 | Sponsor Protocol Number: AI452-017 | Start Date*: 2012-11-20 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, with and without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combina... | |||||||||||||
Medical condition: Chronic Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) FI (Completed) NL (Completed) IT (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004021-25 | Sponsor Protocol Number: IM026-024 | Start Date*: 2021-10-13 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of BMS-986256 in Participants with Active Systemic Lupus Erythematosus. | |||||||||||||
Medical condition: Active Systemic Lupus Erythematosus. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) ES (Ongoing) PL (Ongoing) IE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003138-17 | Sponsor Protocol Number: P1200_51 | Start Date*: 2020-01-17 | |||||||||||
Sponsor Name:Cliniques universitaires Saint-Luc | |||||||||||||
Full Title: A 24 weeks proof of concept study to evaluate the clinical, MRI and synovial tissue benefit of Sarilumab in active RA patients despite TNF agents | |||||||||||||
Medical condition: Medical condition – Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002288-24 | Sponsor Protocol Number: Ci-FCP001 | Start Date*: 2021-08-10 |
Sponsor Name:Amsterdam UMC | ||
Full Title: Effect of citalopram on chest pain in patients with functional chest pain | ||
Medical condition: Chest pain can be divided in cardiac or non-cardiac chest pain (NCCP). To establish the diagnosis NCCP, acute coronary disease has to be ruled out first. NCCP can be caused by functional chest pain... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-003280-22 | Sponsor Protocol Number: AI452-032 | Start Date*: 2013-08-13 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: Phase 3 open label study evaluating the efficacy and safety of pegylated interferon lambda-1a, in combination with ribavirin and daclatasvir, for treatment of chronic HCV infection with treatment n... | |||||||||||||
Medical condition: Chronic Hepatitis C Virus (HCV) Infection (Genotypes 1, 2, 3, 4) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) IT (Completed) DE (Completed) ES (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000299-13 | Sponsor Protocol Number: NVD003-CLN01 | Start Date*: 2018-05-17 |
Sponsor Name:Novadip Biosciences | ||
Full Title: A prospective multicentre single-arm study in adults to evaluate the safety and preliminary efficacy of the autologous 3D osteogenic implant NVD-003 for bone reconstruction for the treatment of rec... | ||
Medical condition: Patients with documented recalcitrant lower limb nonunion, meaning a single, meta- and/or diaphyseal nonunion defect of femur or tibia after at least one failed reconstructive surgical attempt. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Ongoing) LU (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004740-36 | Sponsor Protocol Number: PTCEMF-GD-004 | Start Date*: 2019-10-14 | |||||||||||
Sponsor Name:PTC Therapeutics, Inc. | |||||||||||||
Full Title: A MULTICENTER RANDOMIZED PLACEBO-CONTROLLED PHASE 3 STUDY ON THE SAFETY AND EFFICACY OF DEFLAZACORT (EMFLAZA®) IN SUBJECTS WITH LIMB-GIRDLE MUSCULAR DYSTROPHY 2I (LGMD2I | |||||||||||||
Medical condition: Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005409-65 | Sponsor Protocol Number: AI452-021 | Start Date*: 2013-01-18 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 3 Evaluation of Daclatasvir in Combination with Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination with Peginterferon Alfa-2a and RBV in Patients with Chronic Hepatiti... | |||||||||||||
Medical condition: Chronic Hepatitis C Virus Infection (Genotype 1b) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) IT (Completed) DE (Completed) PL (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003508-11 | Sponsor Protocol Number: AI452-033 | Start Date*: 2013-08-09 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Double-Blinded, Randomized Control Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a Compared to Peginterferon alfa-2a, Each in Combination with Ribavirin, in the Treatment of N... | |||||||||||||
Medical condition: Chronic Hepatitis C Virus Infection (Genotype 1) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-005023-92 | Sponsor Protocol Number: 4658-203 | Start Date*: 2017-03-28 | |||||||||||
Sponsor Name:Sarepta Therapeutics, Inc. | |||||||||||||
Full Title: An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy | |||||||||||||
Medical condition: Patients with Duchenne Muscular Dystropy Amenable to Exon 51 Skipping | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-005024-28 | Sponsor Protocol Number: 4658-204 | Start Date*: 2017-03-28 | |||||||||||
Sponsor Name:Sarepta Therapeutics, Inc. | |||||||||||||
Full Title: An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy | |||||||||||||
Medical condition: Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003697-17 | Sponsor Protocol Number: CNTO1959PSA2001 | Start Date*: 2015-04-22 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Active Psoriatic Arthritis | |||||||||||||
Medical condition: Active Psoriatic Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004139-21 | Sponsor Protocol Number: CTU/2017/306 | Start Date*: 2020-04-22 | ||||||||||||||||
Sponsor Name:University College London | ||||||||||||||||||
Full Title: A randomised prospective open label pilot trial comparing mycophenolate mofetil (MMF) with no immunosuppression in adults with limited cutaneous systemic sclerosis MINIMISE-Pilot (Mycophenolate in ... | ||||||||||||||||||
Medical condition: Limited cutaneous systemic sclerosis (lcSSc) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000307-24 | Sponsor Protocol Number: A0031005 | Start Date*: 2022-05-03 |
Sponsor Name:Pfizer Inc. | ||
Full Title: AN OPEN LABEL NON-RANDOMIZED STUDY TO CHARACTERIZE THE STEADY STATE PHARMACOKINETICS OF SULFASALAZINE DELAYED RELEASE TABLETS IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS | ||
Medical condition: Juvenile Idiopathic Arthritis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.